Wire · operational-macro
First drug to treat Alexander disease approved by the FDA after three decades of research
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 22 September 2026 · Fusion42 review
The FDA approved Zanvastro, the first disease-modifying drug for Alexander disease, a rare neurological disorder. Developed after more than 30 years of research at the University of Wisconsin–Madison and Ionis Pharmaceuticals, Zanvastro targets the GFAP protein central to the disease's progression.
This Wire brief sits within Fusion42's coverage of Biotech, and 15 sources have reported it between 3 Sep 2026 and 22 Sep 2026.
◆ ◆ The Wire takeaway
Zanvastro's FDA approval opens a new market for rare neurological diseases previously untreatable beyond symptoms. You can now explore antisense oligonucleotide therapies targeting genetic root causes in ultra-rare conditions.
◆ Coverage
15 sources · first reported 3 Sep 2026 · latest 22 Sep 2026
◆ Related on Wire
◆ Topics